http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Kwanghyun,Yu, Sunyoung,Kim, Sung-Wook,Kim, Taegeon,Kim, Sang-Min,Kang, Se-Young,Han, Seung Min,Jang, Ji-Hyun The Royal Society of Chemistry 2017 Chemical communications Vol.53 No.58
<▼1><P>This is the first report on the fabrication of defect-free submicron structures with more than 100 μm thickness and an aspect ratio over 100.</P></▼1><▼2><P>This is the first report on the fabrication of defect-free submicron structures with more than 100 μm thickness and an aspect ratio over 100. Highly transparent poly(glycidyl methacrylate-<I>co</I>-acryloisobutyl POSS) (PGP) was synthesized <I>via</I> radical polymerization. The mechanical properties of the PGP submicron structure displayed a Young's modulus of 6.09 GPa and a hardness of 0.16 GPa, 4.2 and 8 times, respectively, than those of SU8 nanopatterns. These enhancements enable the utilization of ultrathick 2D-/3D-submicron structures as an ideal platform for microelectromechanical systems, big data storage systems, energy devices, <I>etc.</I></P></▼2>
IRF7 promotes glioma cell invasion by inhibiting AGO2 expression.
Kim, Jun-Kyum,Jin, Xiong,Ham, Seok Won,Lee, Seon Yong,Seo, Sunyoung,Kim, Sung-Chan,Kim, Sung-Hak,Kim, Hyunggee Saikon Pub. Co 2015 TUMOR BIOLOGY Vol.36 No.7
<P>Interferon regulatory factor 7 (IRF7) is the master transcription factor that plays a pivotal role in the transcriptional activation of type I interferon genes in the inflammatory response. Our previous study revealed that IRF7 is an important regulator of tumor progression via the expression of inflammatory cytokines in glioma. Here, we report that IRF7 promotes glioma invasion and confers resistance to both chemotherapy and radiotherapy by inhibiting expression of argonaute 2 (AGO2), a regulator of microRNA biogenesis. We found that IRF7 and AGO2 expression levels were negatively correlated in patients with glioblastoma multiforme. Ectopic IRF7 expression led to a reduction in AGO2 expression, while depletion of IRF7 resulted in increased AGO2 expression in the LN-229 glioma cell line. In an in vitro invasion assay, IRF7 overexpression enhanced glioma cell invasion. Furthermore, reconstitution of AGO2 expression in IRF7-overexpressing cells led to decreased cell invasion, whereas the reduced invasion due to IRF7 depletion was rescued by AGO2 depletion. In addition, IRF7 induced chemoresistance and radioresistance of glioma cells by diminishing AGO2 expression. Finally, AGO2 depletion alone was sufficient to accelerate glioma cell invasion in vitro and in vivo, indicating that AGO2 regulates cancer cell invasion. Taken together, our results indicate that IRF7 promotes glioma cell invasion and both chemoresistance and radioresistance through AGO2 inhibition.</P>
중증 허혈성 지체질환 환자에서 시행된 vascular endothelial growth factor의 혈관신생 유전자치료 1예
김현중,장신이,김종묵,김선영,김병문,김원배,김덕경 대한내과학회 2003 대한내과학회지 Vol.64 No.1
저자 등은 기존의 치료에 반응하지 않은 중증 허혈성 지체질환 환자를 대상으로 하여 vascular endothelial growth factor를 이용한 혈관신생 유전자 치료를 시행하였다. 치료 후 환자의 허혈에 의한 하지 통증이 현격하게 감소하고 상처의 진행이 측부혈관이 많이 증가됨이 관찰되어 이에 문헌고찰과 함께 보고하는 바이다. We report VEGF-induced angiogenic gene therapy in a patient with critical limb ischemia, who did not respond to conventional treatment. This patient was the first case in a dose-escalating series of phase I clinical trial. The patient had severe resting pain, gangrene and diffuse ulcer in his left foot. Total 1,000㎍ of naked DNA encoding human VEGF165 was administered intramuscularly to 8 sites of the loft lower extremity. Four weeks after the first 1,000㎛ was administered to the same sites (total dose: 2,000㎛). After gene therapy, resting pain gradually reduced and the amount of analgesics taken by the patient decreased. The ischemic wound of lower extremity slightly improved. However, there was no complete wound healing at 12 weeks of treatment. Digital subtraction angiography at 12 weeks after gene therapy showed an increase in collateral vessels at the mid-tibial, ankle and foot arch levels. Immediately and up to 12 weeks, there was no complication related to gene therapy. These findings may be cautiously interpreted to indicate that intramuscular injection of naked plasmid DNA of VEGF_165 may induce therapeutic angiogencsis in a patient with critical limb ischemia. Further clinical evaluation of VEGF-induced gene therapy is needed to evaluate the safety and efficiency of this treatment.(Korean J Med 64:85-90, 2003)
Sunyoung Cho(Sunyoung Cho),Heejo Koo(Heejo Koo),Beom Kyung Kim(Beom Kyung Kim),Euna Han(Euna Han) 대한약학회 2024 약학회지 Vol.68 No.1
Many studies have shown that statins reduce the risk of progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC) among at-risk populations. However, causality has not been proved. This study examined whether statins could prevent LC and HCC in patients with progressive and worsening chronic liver disease, using a robust methodology for causality. Between 2002 and 2013, 52,145 patients with chronic liver diseases were identified from the National Health Insurance Service database in South Korea. The inverse probability weighting (IPW) and superlearning targeted maximum likelihood estimation (TMLE) were used to assess the causality of statin use on the risk of LC and HCC, adjusting for sex, age, comorbidities, and co-medications. Multivariable superlearning TMLE revealed that statin use was associated with reduction in the incidence risk of LC (Marginal odds ratio (MOR) 0.59, 95% confidence interval [CI] 0.50-0.65) and HCC (MOR 0.59, 95% CI 0.50-0.67). Such a protective effect was more evident with atorvastatin and lipophilic statin. This population-based observational study indicated the benefit of statin use, particularly atorvastatin and lipophilic statin, for causally reducing the risk of LC and HCC.
Effects of Hormone Replacement Therapy on Bone Mineral Density in Korean Adults With Turner Syndrome
Kim SunYoung,Kim Heeyon,Lee Inha,Choi Euna,Baek JinKyung,Lee Jaekyung,Kim Hae-Rim,Yun Bo Hyon,Choi Young Sik,Seo Seok Kyo 대한의학회 2024 Journal of Korean medical science Vol.39 No.1
Background: Turner syndrome (TS) is a common chromosomal abnormality, which is caused by loss of all or part of one X chromosome. Hormone replacement therapy in TS is important in terms of puberty, growth and prevention of osteoporosis however, such a study has never been conducted in Korea. Therefore, the purpose of our study was to determine relationship between the starting age, duration of estrogen replacement therapy (ERT) in TS and develop a hormone replacement protocol suitable for the situation in Korea. Methods: This is retrospective study analyzed the medical records in TS patients treated at the Severance hospital, Yonsei University College of Medicine, Seoul, Korea from 1997 to 2019. Total of 188 subjects who had received a bone density test at least once were included in the study. Korean National Health and Nutrition Examination Survey (KNHANES) was used for achieving bone mineral density (BMD) of normal control group. Student’s t-test, MannWhitney U test, ANOVA and correlation analysis were performed using SPSS 18.0. Results: Each BMD measurement was significantly lower in women with TS than in healthy Korean women. Early start and longer duration of ERT is associated with higher lumbar spine BMD but not femur neck BMD. Femur neck BMD, but not lumbar spine BMD was significantly higher in women with mosaicism than 45XO group. Conclusion: Early onset and appropriate duration of hormone replacement therapy is important for increasing bone mineral density in patients with Turner syndrome. Also, ERT affects differently to TS patients according to mosaicism.